BioNTech Investor Day Presentation Deck
BNT312
Bispecific antibody designed to strengthen T cell and APC synapse
Inert Fc, double conditional,
dual CD40×4-1BB agonist
D
GEN1042
(BNT312)
4-1BB-expressing cell
(eg, T cell)
BNT311 binding affinity:
KD CD40 1.0 nmol/L,
4-1 BB: 0.17 nmol/L
Conditional
4-1BB agonist
activity
4-1BB
GEN1042
CD40
Conditional
CD40 agonist
activity
CD40-expressing APC
(eg, dendritic cell)
APC maturation,
Conditional CD40-stimulation of APC and
conditional 4-1BB mediated stimulation of T cells
T cell
T cell
Enhanced
natural killer (NK)
cell activity
Expression of
costimulatory molecules
e.g. HLA-DR, CD86
Production of
stimulatory cytokines
GEN1042
Activated
dendritic
CD86/HLA-DR
Tumor draining
lymph node
4-1BB
Tumor
lysis
CD40
Tumor
00 Granzyme
Perforin
Granzymes,
perforins
Activated
coll
Blood vessel
Proliferation
Activated
T cell
Differentiation
Memory
T cell
Cytokines
TCR-MHC
receptors
Tumor
lysis
Enhanced effector
T cell activity
Cytokines
Y
T cell proliferation
and differentiation
CD28/CD80
receptors
Protein therapeutics
"Double-conditional" "dual-agonist" molecule for two preclinically validated targets:
CD40: stimulatory receptor primarily expressed on APCs. Engagement of CD40 leads to activation and maturation of APC s
4-1BB: costimulatory tumor necrosis factor expressed on T-cells and NK-cells. Activating the 4-1BB pathway enhances
T cell proliferation, T cell effector functions, and prevents T cell death
Inert Fc to avoid unwanted immune cells crosslinking
BNT312 (Gen1042) is partnered with Genmab based on 50/50 sharing of costs and profits; ¹ Muik A, et al. J Immunother Cancer 2022;0:e004322. doi:10.1136/jitc-2021-004322.
BIONTECH
124View entire presentation